Stockscreener 앱 받기
4.37
1.58%
-0.07
전일 마감가:
$4.44
열려 있는:
$4.48
하루 거래량:
206.46K
Relative Volume:
1.01
시가총액:
$247.13M
수익:
$34.16M
순이익/손실:
$-98.43M
주가수익비율:
-1.8675
EPS:
-2.34
순현금흐름:
$-119.33M
1주 성능:
-1.80%
1개월 성능:
-6.82%
6개월 성능:
+1.16%
1년 성능:
-17.55%
1일 변동 폭
$4.295
$4.50
1주일 범위
$4.295
$4.5912
52주 변동 폭
$2.9448
$6.7899
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
명칭
Foghorn Therapeutics Inc
전화
617-586-3100
주소
500 TECHNOLOGY SQUARE, CAMBRIDGE
FHTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.37 | 251.09M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-07 | 개시 | Guggenheim | Buy |
| 2025-09-17 | 재개 | B. Riley Securities | Buy |
| 2025-04-23 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-01-30 | 개시 | B. Riley Securities | Buy |
| 2024-09-03 | 개시 | Jefferies | Buy |
| 2024-08-19 | 개시 | Evercore ISI | Outperform |
| 2023-03-28 | 개시 | BofA Securities | Buy |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-22 | 개시 | H.C. Wainwright | Buy |
| 2020-11-17 | 개시 | Cowen | Outperform |
| 2020-11-17 | 개시 | Goldman | Buy |
| 2020-11-17 | 개시 | Morgan Stanley | Overweight |
| 2020-11-17 | 개시 | Wedbush | Outperform |
모두보기
Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스
Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast - Defense World
Platform Technologies Drive $211B Surge in Precision Cancer Treatment - marketscreener.com
Analyst Confidence Rises for Foghorn Therapeutics Following Leadership and Pipeline Updates - AD HOC NEWS
Foghorn Therapeutics (NASDAQ:FHTX) Stock Rating Lowered by Wall Street Zen - Defense World
Is Foghorn Therapeutics Inc. stock attractive for hedge fundsJobs Report & AI Driven Stock Reports - Newser
Stifel Initiates Coverage of Foghorn Therapeutics (FHTX) with Buy Recommendation - Nasdaq
Stifel Initiates Coverage on FHTX with a 'Buy' Rating | FHTX Sto - GuruFocus
Foghorn Therapeutics Appoints Interim CFO Jeff Sacher - TipRanks
Foghorn Therapeutics Inc appoints Jeff Sacher as interim CFO - marketscreener.com
Foghorn Therapeutics appoints Jeff Sacher as interim CFO and treasurer By Investing.com - Investing.com Nigeria
Foghorn Therapeutics appoints Jeff Sacher as interim CFO and treasurer - Investing.com
Why Foghorn Therapeutics Inc. stock remains on buy listsJuly 2025 Price Swings & Reliable Momentum Entry Alerts - Newser
Stifel initiates Foghorn Therapeutics stock with Buy rating, $12 target By Investing.com - Investing.com South Africa
Stifel initiates Foghorn Therapeutics stock with Buy rating, $12 target - Investing.com
R/R Acute Myeloid Leukemia Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Foghorn Therapeutics, AB Science, Oncoceutics, Sanofi - Barchart.com
Published on: 2025-12-02 00:54:46 - Newser
Volatility Watch: Will Foghorn Therapeutics Inc stock deliver better than expected guidanceBond Market & Verified Momentum Stock Ideas - BỘ NỘI VỤ
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Recommendation of “Buy” from Analysts - Defense World
What analysts say about Foghorn Therapeutics Inc stockMarket Sentiment Extremes & Maximum Profit Growth - earlytimes.in
Foghorn Therapeutics (NASDAQ:FHTX) Upgraded at Wall Street Zen - MarketBeat
Foghorn Therapeutics CEO joins Evercore Healthcare Conference - Traders Union
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference - The Manila Times
Foghorn Therapeutics (Nasdaq: FHTX) to Join 8th Evercore Healthcare Conference - Stock Titan
Why Foghorn Therapeutics Inc. stock is a must watch in 2025Quarterly Performance Summary & Fast Moving Market Watchlists - newser.com
Can Foghorn Therapeutics Inc. stock maintain growth trajectory2025 Performance Recap & Risk Controlled Daily Plans - newser.com
How Foghorn Therapeutics Inc. stock reacts to Fed rate cutsJuly 2025 Momentum & Weekly Market Pulse Alerts - newser.com
How Foghorn Therapeutics Inc. stock valuations compare to rivalsQuarterly Portfolio Report & Consistent Profit Trading Strategies - newser.com
Is Foghorn Therapeutics Inc. stock safe for conservative investorsQuarterly Portfolio Report & Verified Momentum Watchlists - newser.com
Is Foghorn Therapeutics Inc. stock bottoming outShare Buyback & Fast Gain Stock Tips - newser.com
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 133.27% as Wall Street Analysts Expect? - Zacks Investment Research
FHTX: SMARCA2 program advances with Lilly partnership; multiple novel assets near IND and strong funding - TradingView
Identifying reversal signals in Foghorn Therapeutics Inc.July 2025 Action & AI Enhanced Trading Signals - newser.com
How Foghorn Therapeutics Inc. stock compares to growth peers2025 Top Gainers & Smart Investment Allocation Tips - newser.com
Check Out Foghorn Therapeutics Inc (FHTX)’s Trade Data Rather Than the Analysts’ Views - Setenews
Foghorn Therapeutics Inc (FHTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.05%
자본화:
|
볼륨(24시간):